-
NEWS
Tongling Bionics Honored as National "Little Giant" Enterprise by MIIT
2024-09-10
Recently, the Ministry of Industry and Information Technology (MIIT) announced the sixth batch of specialized and sophisticated "Little Giant" enterprises, with Anhui Tongling Bionics Technology Ltd. being recognized. This prestigious accreditation reaffirms the company's strong technological capabilities and tremendous growth potential.
The specialized and sophisticated small and medium-sized enterprises (SMEs) are characterized by their specialization, sophistication, uniqueness and novelty.Among them, the "Little Giant" enterprises represent the cream of the crop - they occupy pivotal positions in fundamental industrial sectors and key supply chain links, demonstrating outstanding innovation capabilities, mastery of core technologies, dominant shares in niche markets, and excellent quality-efficiency performance. These enterprises form the backbone of high-quality small and medium-sized businesses, serving as the vanguard in developing new quality productive forces.
Since its inception, Tongling Bionics has remained committed to developing world-leading, whole-life-cycle solutions for heart failure diagnosis, treatment and rehabilitation. Through persistent innovation and dedicated refinement, the company has continuously broken through technological barriers and established an increasingly comprehensive product portfolio.
The percutaneous Ventricular Assist Device (pVAD) system represents China's first domestically developed, internationally competitive high-end medical device. By implanting a catheter pump into the patient's ventricle to actively augment cardiac output and reduce myocardial workload, it provides crucial hemodynamic support for severe heart failure patients. Currently in multicenter clinical trials across China with promising progress, this product is poised to fill a critical domestic market gap.
Similarly, the Intra-Aortic Balloon Pump (IABP) offers hemodynamic support for severe heart failure patients through precisely timed inflation/deflation of an intra-aortic balloon to improve myocardial oxygen supply-demand balance. Featuring intelligent operation, enhanced safety, and compact design, this product has entered the registration phase and is expected to become China's first domestically produced IABP, breaking foreign monopolies.
The Enhanced External Counterpulsation (EECP) device provides non-invasive treatment for cardiovascular diseases. By rhythmically inflating/deflating cuffs around the patient's calves, thighs and buttocks, it enhances blood perfusion while reducing cardiac afterload. Recently receiving market authorization, this next-generation device outperforms conventional products with better cuff fit, stronger pneumatic delivery, and superior hemodynamic control algorithms for improved therapeutic outcomes.
The Impedance Cardiography (ICG) monitor employs advanced thoracic bioimpedance technology to non-invasively measure 16 key hemodynamic parameters (including cardiac output) in real-time, supporting both static and dynamic monitoring. Praised by medical institutions for its safety, reliability, user-friendliness and repeatability, it meets diverse clinical needs from early prevention to treatment and rehabilitation.
Looking ahead, Tongling Bionics will continue strengthening its heart failure product ecosystem, maintaining its first-mover advantage in specialized segments while driving cutting-edge innovations to safeguard human health.
Latest News
Anhui Tongling Bionics Technology Ltd.
Anhui Tongling Bionics Technology Ltd.
Copyright © 2025 Anhui Tongling Bionics Technology Ltd.
Copyright © 2025 Anhui Tongling Bionics Technology Ltd.